CVKD Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
3.3M
+32.9%
2.5M
-18.0%
3.1M
+12.1%
2.7M
-26.8%
3.7M
R&D
705.2K
-8.6%
771.5K
+15.8%
666.3K
-3.2%
688.5K
-36.1%
1.1M
SG&A
2.6M
+51.2%
1.7M
-27.3%
2.4M
+17.3%
2.0M
-23.0%
2.7M
Operating Income
-3340400
-32.9%
-2514378
+18.0%
-3065106
-12.1%
-2733803
+26.8%
-3734291
EBITDA
-3339896
-32.9%
-2513823
+18.0%
-3064551
-12.1%
-2733402
+26.8%
-3733890
Net Income
-3322565
-33.1%
-2496540
+17.8%
-3038990
-13.2%
-2685705
+26.8%
-3667287
EPS (Basic)
$-1.14
-9.6%
$-1.04
+27.3%
$-1.43
-9.2%
$-1.31
+29.9%
$-1.87
EPS (Diluted)
$-1.14
-9.6%
$-1.04
+27.3%
$-1.43
-9.2%
$-1.31
+29.9%
$-1.87
Shares (Diluted)
2.9M
+21.0%
2.4M
+13.3%
2.1M
+4.0%
2.0M
+4.2%
2.0M
Cadrenal Therapeutics (CVKD) โ€” Financials